A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological
/ administration & dosage
B7-H1 Antigen
/ antagonists & inhibitors
Biomarkers, Tumor
/ blood
Blood Proteins
/ classification
Carcinoma, Non-Small-Cell Lung
/ blood
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Immune Checkpoint Inhibitors
/ administration & dosage
Machine Learning
Male
Middle Aged
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Progression-Free Survival
Prospective Studies
Proteomics
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
13
02
2020
revised:
10
05
2020
accepted:
30
06
2020
pubmed:
8
7
2020
medline:
26
11
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Pretreatment selection of patients with non-small cell lung cancer (NSCLC) who would derive clinical benefit from treatment with immune checkpoint inhibitors (CPIs) would fulfill an unmet clinical need by reducing unnecessary toxicities from treatment and result in substantial health care savings. In a retrospective study, mass spectrometry (MS)-based proteomic analysis was performed on pretreatment sera derived from patients with advanced NSCLC treated with nivolumab as part of routine clinical care ( A signature consisting of 274 MS features derived from a development set of 116 patients was associated with progression-free survival (PFS) and overall survival (OS) across two validation cohorts ( This serum-derived protein signature successfully stratified outcomes in cohorts of patients with advanced NSCLC treated with second-line PD-1 CPIs and deserves further prospective study.
Identifiants
pubmed: 32631957
pii: 1078-0432.CCR-20-0538
doi: 10.1158/1078-0432.CCR-20-0538
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
Biomarkers, Tumor
0
Blood Proteins
0
CD274 protein, human
0
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5188-5197Informations de copyright
©2020 American Association for Cancer Research.